Announcements
6 March 2025
Welcoming New Editorial Board Members of Cancers Joined in January 2025
5 March 2025
Cancers | Kidney Cancer Awareness Month
27 February 2025
More than 300 MDPI Journals Indexed in Web of Science
MDPI is pleased to share a significant milestone in its mission to advance scholarly research and promote the dissemination of knowledge—300+ MDPI journals are now indexed in Web of Science (WoS). This milestone highlights the global recognition, interdisciplinary impact and enhanced visibility of our journals. It also reflects our adherence to rigorous editorial standards, scientific integrity, and our mission to foster open scientific exchange in all forms, across all disciplines.
To explore the full list of our journals indexed in WoS, please visit https://www.mdpi.com/about/journals/wos. Beyond expanding the coverage of our publications in the leading academic databases, we are dedicated to ensuring that our journals are included in as many scope-specific databases as possible. This increases the visibility of our authors’ work and extends the reach of their significant data.
This milestone would not have been possible without the efforts and expertise of our academic editors, reviewers and authors. Their commitment and collaboration have been instrumental in creating an inclusive, accessible, and impactful publishing platform. We also extend our gratitude to the global research community for their trust as we continue to break new ground in academic publishing. This milestone is not just a celebration of MDPI’s progress but also recognition of the collective strides made by researchers worldwide.
As we celebrate this remarkable accomplishment, MDPI remains steadfast in its commitment to open access publishing and ensuring that high-quality research reaches and inspires a global audience.
17 February 2025
MDPI Celebrates Excellence in Medical Research with Early Career Researcher Awards
MDPI, a pioneer in scholarly open access publishing, and the Lee Kong Chian School of Medicine (LKCMedicine), Singapore, proudly announce the successful conclusion of the first edition the MDPI Early Career Researcher Awards. The awards, which recognize outstanding contributions to medical and biomedical research, were presented to six exceptional researchers during an awards ceremony held at LKCMedicine HQ Building on 28 November 2024.
|
|
|
Honoring Excellence in Research
The awards recognize exceptional postdoctoral researchers and Ph.D. students who have demonstrated outstanding originality, innovation, and impact in their respective fields. We are honored to announce the winners of the 2024 edition:
Early Career Researcher (Postdoc) Award:
- Dr. Theresia Handayani Mina, “Adiposity and Metabolic Health in Asian Populations: An Epidemiological Study Using Dual-Energy X-Ray Absorptiometry in Singapore”;
- Dr. Erfan Rezvani Ghomi, “Wound Healing Improvement by Novel Aligned Antimicrobial Nanofibrous 3D Scaffolds”;
- Dr. Yadollah Ranjbar Slamloo, “Functional Alterations of The Prefrontal Circuit Underlying Cognitive Aging in Mice”.
Early Career Researcher (Ph.D.) Award:
- Pritisha Rozario, “Mechanistic Basis for Potassium Efflux-Driven Activation of the Human NLRP1 Inflammasome”;
- Michelle Law Cheok Yien, “Chikungunya Virus Nonstructural Protein 1 is a Versatile RNA Capping and Decapping Enzyme”;
- Yin Ruoyu, “The Use of Digital Mental Health and Wellbeing Tools in Older Adults: A Mixed Method Study”.
Our collaboration highlights a shared commitment to recognizing exceptional talent and research within the academic community, addressing today’s healthcare challenges, and inspiring continued innovation.
|
|
|
|
|
|
|
|
|
Looking Ahead to 2025
Building on the success of the first edition, MDPI and LKCMedicine are excited to announce that the 2025 MDPI Early Researcher Awards will continue to celebrate excellence and innovation in medical research. The next edition promises to expand its scope, introducing new categories and providing even greater recognition for impactful research.
Further details on the 2025 awards, including nomination criteria and timelines, will be shared in the coming months. We remain committed to fostering a culture of research excellence and collaboration within the global scientific community.
|
|
12 February 2025
Welcoming New Editorial Board Members of Cancers Joined in December 2024
We are pleased to announce that seven new scholars have been appointed as Editorial Board Members (EBMs) of Cancers (ISSN: 2072-6694), joining in December 2024. We wish our new members success in both their research and their efforts to develop the journal.
Name: Prof. Dr. Franz Rödel
Affiliation: Department of Radiotherapy and Oncology, Goethe University Frankfurt am Main, 60590 Frankfurt am Main, Germany
Interests: translational research; biomarker development; cancer radioimmunotherapy; low-dose anti-inflammatory radiation therapy; tumor microenviroment; survivin; molecular targeting
Name: Prof. Dr. Junya Fujimoto
Affiliation: Department of Translational Molecular Pathology (Affiliated Department in Hospital), Clinical Research Center in Hiroshima, Hiroshima University Hospital, Hiroshima 734-8551, Japan
Interests: molecular pathology; lung cancer; pre-malignant cancer; intra-tumor heterogeneity; system biorepository for multimodal integration; translational research
Name: Dr. Gianluca Tomasello
Affiliation: Oncology Division, ASST Crema, Ospedale Maggiore di Crema, Largo U. Dossena 2, 26013 Crema, CR, Italy
Interests: breast cancer; gastrointestinal cancers; clinical trials
Name: Prof. Dr. Matteo Donadon
Affiliations: 1 Department of Health Sciences, University of Piemonte Orientale, 28100 Novara, Italy; 2 Division of General Surgery, University Maggiore Hospital della Carità, 28100, Novara, Italy
Interests: cholangiocarcinoma; Klatskin tumor; colorectal liver metastases; neuroendocrine tumors; hepatocellular carcinoma; hepatic resection; hepatectomy; liver resection; liver surgery; parenchymal-sparing liver surgery; intraoperative ultrasound; liver-specific magnetic resonance imaging; trans-arterial therapy; liver function; FibroScan; pancreatic tumor; pancreatic resection; laparoscopic surgery; robotic surgery
Name: Dr. Evangelos Kolettas
Affiliations: 1 Laboratory of Biology, School of Medicine, Faculty of Health Sciences, Institute of Biosciences, University Research Centre, University of Ioannina, 451 10 Ioannina, Greece; 2 Molecular Cancer Biology & Senescence Labortaory, Biomedical Research Institute (BRI), Foundation for Research and Technology (FORTH), Ioannina, Greece
Interests: cancer; senescence; DNA damage; inflammation; epithelial-to-mesenchymal cell transition; cell signalling; NF-kappaB; transcriptional regulation; epigenetics; miRNA
Name: Dr. Gianluca Tenore
Affiliation: Department of Oral and Maxillofacial Sciences, Sapienza University of Rome, 00161 Rome, Italy
Interests: oral medicine; oral pathology; oral cancer; oral surgery; laser in dentistry
Name: Dr. Giovanni Luca Ceresoli
Affiliation: Department of Oncology, Thoracic and Urologic Oncology Unit, Cliniche Humanitas Gavazzeni, via Gavazzeni 21, 24125 Bergamo, Italy
Interests: malignant pleural mesothelioma (main); lung cancer; prostate cancer; renal cancer
Further details about the Editorial Board of Cancers can be found by clicking the following link: https://www.mdpi.com/journal/cancers/editors.
Cancers is recruiting scholars from around the world to join our Editorial Board. To apply for membership, recommend potential candidates, or request further information, please contact the Cancers Editorial Office (cancers@mdpi.com) and provide the following files:
- A full academic CV;
- A short cover letter detailing your interest in the position.
7 February 2025
Cancers | Highly Viewed Papers in 2024 and Hot Topic Special Issues on Cancer Drug Development
We are delighted to share some highly viewed papers on cancer drug development that were published in Cancers (ISSN: 2072-6694) in 2024. In addition, some Special Issues on this topic are open for submission. The following is a list of articles and Special Issues that we believe will interest you.
The list of relevant papers can be seen below:
“Antibody–Drug Conjugates: The Dynamic Evolution from Conventional to Next-Generation Constructs”
by Virginia Metrangolo and Lars H. Engelholm
Cancers 2024, 16(2), 447; https://doi.org/10.3390/cancers16020447
Available online: https://www.mdpi.com/2072-6694/16/2/447
“Targeted Nanoparticle-Based Diagnostic and Treatment Options for Pancreatic Cancer”
by Xin Gu and Tamara Minko
Cancers 2024, 16(8), 1589; https://doi.org/10.3390/cancers16081589
Available online: https://www.mdpi.com/2072-6694/16/8/1589
“Peptide Therapeutics: Unveiling the Potential against Cancer—A Journey through 1989”
by Othman Al Musaimi
Cancers 2024, 16(5), 1032; https://doi.org/10.3390/cancers16051032
Available online: https://www.mdpi.com/2072-6694/16/5/1032
“Understanding Cancer’s Defense against Topoisomerase-Active Drugs: A Comprehensive Review”
by Nilesh Kumar Sharma, Anjali Bahot, Gopinath Sekar, Mahima Bansode, Kratika Khunteta, Priyanka Vijay Sonar, Ameya Hebale, Vaishnavi Salokhe and Birandra Kumar Sinha
Cancers 2024, 16(4), 680; https://doi.org/10.3390/cancers16040680
Available online: https://www.mdpi.com/2072-6694/16/4/680
“Innovations in Antibody-Drug Conjugate (ADC) in the Treatment of Lymphoma”
by Ali Al Sbihi, Maryam Alasfour and Georgios Pongas
Cancers 2024, 16(4), 827; https://doi.org/10.3390/cancers16040827
Available online: https://www.mdpi.com/2072-6694/16/4/827
“DDX3X and Stress Granules: Emerging Players in Cancer and Drug Resistance”
by Han Zhang, Paula M. Mañán-Mejías, Hannah N. Miles, Andrea A. Putnam, Leonard R. MacGillivray and William A. Ricke
Cancers 2024, 16(6), 1131; https://doi.org/10.3390/cancers16061131
Available online: https://www.mdpi.com/2072-6694/16/6/1131
Special Issues:
|
“Drug Targeting Therapy in Multiple Myeloma” |
“Recent Advances in PROteolysis TArgeting Chimeras (PROTACs)” |
|
|
|
|
“Understanding the Complexities of Anticancer Drugs Resistance” |
“Drug Repurposing and Reformulation for Cancer Treatment: 2nd Edition” |
|
|
|
You are invited to view and submit relevant papers to the journal Cancers at the following link: https://www.mdpi.com/journal/cancers.
Cancers Editorial Office
6 February 2025
Cancers | Highly Viewed Papers in 2024 and Hot Topic Special Issues on Cancer Therapy
We are delighted to share some highly viewed papers on cancer epidemiology and prevention that were published in Cancers (ISSN: 2072-6694) in 2024. In addition, some Special Issues on this topic are open for submission. The following is a list of articles and Special Issues that we believe will interest you.
The list of relevant papers can be seen below:
“Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape”
by Emily Kinsey and Hannah M. Lee
Cancers 2024, 16(3), 666; https://doi.org/10.3390/cancers16030666
Available online: https://www.mdpi.com/2072-6694/16/3/666
“Prognosis and Treatment of Gastric Cancer: A 2024 Update”
by Claudia Burz, Vlad Pop, Ciprian Silaghi, Iulia Lupan and Gabriel Samasca
Cancers 2024, 16(9), 1708; https://doi.org/10.3390/cancers16091708
Available online: https://www.mdpi.com/2072-6694/16/9/1708
“Interplay of Ferroptosis and Cuproptosis in Cancer: Dissecting Metal-Driven Mechanisms for Therapeutic Potentials”
by Jinjiang Wang, Jiaxi Li, Jiao Liu, Kit-Ying Chan, Ho-Sze Lee, Kenneth Nansheng Lin, Chi-Chiu Wang and Tat-San Lau
Cancers 2024, 16(3), 512; https://doi.org/10.3390/cancers16030512
Available online: https://www.mdpi.com/2072-6694/16/3/512
“Outcomes and Techniques of Robotic-Assisted Partial Nephrectomy (RAPN) for Renal Hilar Masses: A Comprehensive Systematic Review”
by Savio Domenico Pandolfo, Zhenjie Wu, Riccardo Campi, Riccardo Bertolo, Daniele Amparore, Andrea Mari, Paolo Verze, Celeste Manfredi, Antonio Franco, Francesco Ditonno et al.
Cancers 2024, 16(4), 693; https://doi.org/10.3390/cancers16040693
Available online: https://www.mdpi.com/2072-6694/16/4/693
“Targeted Therapeutic Strategies for the Treatment of Cancer”
by Benjamin Victoir, Cécile Croix, Fabrice Gouilleux and Gildas Prié
Cancers 2024, 16(2), 461; https://doi.org/10.3390/cancers16020461
Available online: https://www.mdpi.com/2072-6694/16/2/461
“Therapies for the Treatment of Advanced/Metastatic Estrogen Receptor-Positive Breast Cancer: Current Situation and Future Directions”
by Rohan Kalyan Rej, Joyeeta Roy and Srinivasa Rao Allu
Cancers 2024, 16(3), 552; https://doi.org/10.3390/cancers16030552
Available online: https://www.mdpi.com/2072-6694/16/3/552
Special Issues:
| “Novel Combinatorial Approaches for Immunotherapy and Targeted Therapies in Cancer” Guest Editors: Dr. Claudia De Lorenzo and Dr. Laura Cerchia Submission deadline: 31 March 2025 |
“Novel Therapeutic Strategies in Salivary Gland Tumor” Guest Editors: Dr. Giovanni Salzano, Dr. Arianna Di Stadio and Dr. Luigi Angelo Vaira Submission deadline: 30 April 2025 |
 |
 |
| “Current Advances in Management of Neuroendocrine Neoplasms” Guest Editors: Dr. Ashley Kieran Clift and Prof. Dr. Andrea Frilling Submission deadline: 30 May 2025 |
“Pulmonary Nodule and Lung Cancer: Diagnosis and Clinical Treatment” Guest Editor: Dr. Morena Fasano Submission deadline: 20 June 2025 |
 |
 |
You are invited to view and submit relevant papers to the journal Cancers at the following link:
https://www.mdpi.com/journal/cancers.
Cancers Editorial Office
5 February 2025
MDPI INSIGHTS: The CEO's Letter #20 - Beijing, Singapore, Bangkok, JAMS, Jisc
Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts
2024 Annual Meeting – Beijing (15 January 2025)
You haven’t truly experienced a New Year’s celebration until you’ve attended one of MDPI’s Chinese Annual Meeting festivities. This year I visited our annual meeting in Beijing, held on the 15th of January.
Imagine this: stepping into a banquet hall filled with 140 tables and about 1,400 colleagues from our Beijing offices, all gathered to share in a six-hour event. The agenda included year-end speeches and presentations, a variety of performances by our colleagues, a selection of awards honouring local employees for their work, group photos for the memories, and a dinner.
This may have been one of the largest events I have attended. For those unaccustomed to such an event, it might seem overwhelming, but it was quite the opposite. The atmosphere was one of celebration as everyone came together to support their peers and celebrate the achievements of 2024.
I was honoured to deliver the opening speech and a presentation highlighting our growth and investment in MDPI’s most valuable asset: our people.
“Our editorial teams represent MDPI at its finest”
I want to give special recognition to the editorial department, across all of our offices, which forms the heart of our business. These teams are the frontline communicators with our authors, reviewers, and guest editors, creating a smooth experience of processing our manuscripts. Their professionalism and kindness are often highlighted as key drivers of satisfaction with MDPI. For this, I extend my deepest gratitude to all our editorial staff, across every office. They truly represent MDPI at its finest.
Beijing is home to two of our offices, with just over 800 employees in Tongzhou and over 600 in Haidian. Thank you to our administrative teams and everyone involved in organizing these New Year’s celebrations across all offices. These events provide a moment to reflect on our shared accomplishments and appreciate the positive impact each of you has on our culture.
MDPI Offices in China
While the history of MDPI begins in Basel, Switzerland, the story of MDPI is very much rooted in China. Below is a list of MDPI’s current offices in China and their respective dates of inauguration:
- 2008: Beijing (Tongzhou, Haidian)
- 2013: Wuhan (Hankou, Guanggu)
- 2019: Tianjin
- 2021: Dalian
- 2021: Nanjing
To date, over 381,000 MDPI research articles have been published by authors affiliated with Chinese institutions, making China our largest market. This is reflected not only in the volume of publications but also in the scale of our workforce supporting local operations and contributing to global success.
While no new offices in China were launched between 2022 and 2024 due to the pandemic and strategic planning, we remain committed to future growth here. Our plans include expanding operations as we continue to build our global workforce.
We look forward to a year filled with continued collaboration, growth, and shared success.
“We remain committed to future growth in China”
Impactful Research
MDPI and Jisc Consortium Extend Open Access Agreement for 2025
I’m pleased to share that MDPI has extended its agreement with the Jisc consortium in the UK for 2025. This renewal strengthens our partnership with UK institutions and reaffirms our shared commitment to advancing open access publishing.
Jisc is the UK’s not-for-profit digital, data, and technology agency supporting tertiary education, research, and innovation. Through initiatives such as our agreement, Jisc helps institutions access essential digital resources and infrastructure to support researchers. Currently, 62 UK institutions are part of our Institutional Open Access Program (IOAP) through this partnership.
Authors from participating institutions benefit from discounts on article processing charges (APCs), with even greater support for institutions that centrally fund APCs. This helps researchers focus on their work while simplifying the publishing process.
A full list of participating institutions can be found here.
As Becky Castellon, our Institutional Partnerships Manager, puts it: “Extending our agreement with Jisc is a reward for the strong partnership we’ve built with research institutions throughout the UK.”
At MDPI, we are dedicated to making research more accessible while reducing administrative burdens for institutions and authors. Open access publishing is at the heart of what we do, and we’re proud to expand its reach in the UK and beyond.
Inside MDPI
Visit to MDPI's Singapore office
During my January trip to some of our APAC offices, I also had the pleasure of visiting our Singapore office for the first time. It’s exciting to see how much the team has grown, now numbering over 55 staff members, with more joining us in February.
Welcoming and Supporting New Team Members
“Experienced staff play an important role in mentoring new hires”
I had the opportunity to connect with both experienced colleagues and new team members who are currently embarking on their careers. This visit reminded me of what it was like when I was in their shoes. I encourage all of us to engage new colleagues with empathy, as we have all been in their position. By creating a welcoming and supportive environment, we can help them settle in and learn about the corporate world, MDPI and our mission.
Experienced staff play an important role in mentoring and guiding new hires, most of whom are transitioning from academia to their first job. I’m especially grateful to colleagues such as Colin Chen, Alicia Ren, Yu Nwe Soe, Colin Wee, Amy Cham and other senior members who have contributed to shaping the culture and work environment in Singapore.
Building MDPI’s Positive Reputation
During my visit, I spoke with the office staff about the importance of their roles in building a positive reputation that helps create trust in MDPI. I shared how every interaction and communication point contributes to the marketing of MDPI and our journals. I also highlighted the career development opportunities available as MDPI continues to grow.
Connecting with the Singapore Marketing Team
I also spent time connecting directly with the Singapore Marketing team, which has quickly grown to 15 young and ambitious members. They are eager to learn and are actively contributing to our journal and corporate marketing activities. I shared insights into our corporate marketing structure and strategy and look forward to supporting them as they grow.
During the visit, I was joined by my colleague Dr. Constanze Schelhorn, Head of Indexing, who provided training on indexing. This training was greatly appreciated by the local staff.
Meeting with Prof. Dr. Manoj Gupta
Lastly, we had the privilege of meeting Prof. Dr. Manoj Gupta, Editor-in-Chief (EiC) of Technologies since 2016 and Section EiC of Metals.
Prof. Gupta is an active decision-maker for the journal and a great brand ambassador for MDPI.
Prof. Gupta has helped sustainably scale Technologies, which now has a 4.2 Impact Factor and a 6.7 CiteScore, ranking Q1 in the JCR category of Engineering and Q1 in the CiteScore category of Computer Science.
During our meeting, we discussed strategies for Institutional Open Access Partnership agreements and ways to promote MDPI journals in Singapore.
PS. During the visit, we also had the chance to participate in Lo Hei, also known as Yee Sang or the “prosperity toss.” This is a raw fish salad traditionally enjoyed during Chinese New Year and is particularly popular among Chinese communities in Singapore, Malaysia, and Indonesia. Everyone gathers around the table as the ingredients are added one by one, and then the salad is mixed together. It was a fun experience to take part in this New Year tradition!
Coming Together for Science
JAMS – Journal & Article Management System
I am excited to announce the official relaunch of JAMS (Journal & Article Management System), one of MDPI’s key initiatives to support academic publishers worldwide.
With this relaunch, JAMS now offers new pricing models and flexible solutions for small-scale journals, commercial publishers, and university presses. We have also redesigned the JAMS website to enhance the user experience.
“JAMS is a testament to our commitment to simplifying the publishing process”
Explore the new website here: jams.pub
It’s also great to see the JAMS team expanding our presence at conferences and on social media to engage more effectively with the academic community.
Recently, Facundo Santomé (Senior Marketing Manager) and Alex Ramos (Senior Marketing Specialist) represented JAMS at the APE 2025 conference in Berlin, highlighting how our platform empowers small and independent publishers to streamline and scale their journal management.
JAMS was built to change that by adapting to the unique requirements of each publisher.
At MDPI, we continually invest in our growth – not only by expanding our operations and staff but also by developing innovative products that serve the academic and publishing community at large. JAMS, with its comprehensive suite of journal management tools, is a testament to our commitment to simplifying the publishing process for our partners.
Imagine a submission system that frees up your time for strategy, innovation, and impactful publishing.
Under the leadership of Silvano Bonfatti (Product Manager, MDPI), the JAMS team has conducted in-depth market research to understand the challenges publishers face: endless administrative tasks, inefficient workflows, and systems that don’t always meet their needs.
If you believe JAMS could benefit any of your network contacts, please share our website. Contact the JAMS team. They are always ready to assist with your publishing needs.
What Sets JAMS Apart?
- Scalability – Whether you're a niche journal or managing thousands of submissions, JAMS grows with you.
- End-to-End Workflow – From submission to peer review and final publication, everything is in one place.
- Automation That Works for You – Say goodbye to chasing reviewers and formatting issues, so that you can focus on quality instead.
- Built by Publishers, for Publishers – JAMS is backed by MDPI’s expertise; we know exactly what it takes to run a journal smoothly.
- Flexible & Fair Pricing – Supporting journals of all sizes, with special rates for non-profits and publishers in the Global South.
Partners Who Already Trust JAMS
If you believe JAMS could benefit any of your network contacts, please share our website. Contact the JAMS team. They are always ready to assist with your publishing needs.
Closing Thoughts
Visit to MDPI's Bangkok office
To conclude my APAC trip, I had the pleasure of visiting our Bangkok office from 22 to 24 January. The office has grown significantly, closing 2024 with a total of 445 colleagues across various departments, including Editorial, Production, Conference, Training, Journal Relationship Specialists (JRS), Managing Editors, and supporting teams in HR, Admin, IT, and Finance.
I would like to praise our Bangkok management team for their excellent work in supporting our growth and creating a positive work environment. Our colleagues here are humble, talented, hardworking, and appreciative of MDPI’s mission.
Thailand was among MDPI’s top 30 markets in 2024 for total publications. With our office in Bangkok, we have an opportunity to further promote open access while supporting local researchers and institutions. This includes open access discounts, author training sessions, conference sponsorships, and other initiatives. We currently have 25 Editorial Board Members (EBMs) from Thailand and will work on expanding this network.
Engaging with Group Leads
“Group leads play an important role in creating a safe, positive environment”
During my visit, I met with our group leads to highlight their crucial role in managing journal performance and mentoring new employees, especially given our increased hiring targets. Many new hires are early in their careers and require training, development, and support. Group leads play an important role in creating a safe, positive environment that fosters professional growth while maintaining MDPI’s reputation for service quality.
To wrap up the session, I added a personal touch by holding the door and giving everyone high-fives – a small gesture to show appreciation, boost morale, and strengthen team spirit. It’s important for our colleagues to feel seen, heard, and valued.
University Visit: King Mongkut’s University of Technology North Bangkok (KMUTNB)
We also visited King Mongkut’s University of Technology North Bangkok (KMUTNB) to explore collaboration opportunities.
Our discussions focused on: Institutional Open Access Partnership (IOAP), Author training sessions, Conference sponsorships, Student employment initiatives, and more.
This visit reinforced the importance of building strong relationships with local universities, ensuring we continue to support and engage with the academic community in Thailand.
“My time in Bangkok was productive and inspiring”
My time in Bangkok was productive and inspiring. The senior team has done a great job in growing the office and creating a supportive, high-performing environment. I look forward to seeing continued success from our colleagues in Thailand.
Chief Executive Officer
MDPI AG
4 February 2025
World Cancer Day 2025—United in Every Journey
Cancer impacts millions of lives worldwide, yet each person’s journey with the disease is uniquely their own. World Cancer Day reminds us that while the disease impacts individuals differently, our shared strength, innovation, and focus on holistic care bring us closer to a future where cancer no longer dictates lives. Every experience, challenge, and success story contribute to the broader fight against cancer, demonstrating the resilience and hope that unite us all. As we continue to make strides through innovative research, treatment advancements, and global collaboration, it is essential to recognize both the diversity of stories and our common goal of overcoming cancer together.
In observance of this day, we invite you to explore the following resources that delve into the field of cancer and the cutting-edge advancements shaping its care. By prioritizing people-centered treatment where patients’ voices and needs guide care, we can ensure personalized attention for all. It is our hope to foster a deeper understanding of the impact of cancer and encourage meaningful action to support patients, caregivers, and researchers in their pursuit of a world free from cancer’s hold. Together, we can inspire action and work toward a cancer-free future.
 |
|
Biology & Life Sciences |
Medicine & Pharmacology |
Chemistry & Material Sciences Public Health & Healthcare Engineering Society |
 |
“Rare Variants of Dermatofibrosarcoma Protuberans: Clinical, Histologic, and Molecular Features and Diagnostic Pitfalls”
by Celestine M. Trinidad, Sintawat Wangsiricharoen, Victor G. Prieto and Phyu P. Aung
Dermatopathology 2023, 10(1), 54–62; https://doi.org/10.3390/dermatopathology10010008
“Nitrogen Containing Heterocycles as Anticancer Agents: A Medicinal Chemistry Perspective”
by Adarsh Kumar, Ankit Kumar Singh, Harshwardhan Singh, Veena Vijayan, Deepak Kumar, Jashwanth Naik, Suresh Thareja, Jagat Pal Yadav, Prateek Pathak, Maria Grishina et al.
Pharmaceuticals 2023, 16(2), 299; https://doi.org/10.3390/ph16020299
“Artificial Intelligence in Brain Tumor Imaging: A Step toward Personalized Medicine”
by Maurizio Cè, Giovanni Irmici, Chiara Foschini, Giulia Maria Danesini, Lydia Viviana Falsitta, Maria Lina Serio, Andrea Fontana, Carlo Martinenghi, Giancarlo Oliva and Michaela Cellina
Curr. Oncol. 2023, 30(3), 2673–2701; https://doi.org/10.3390/curroncol30030203
“Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook”
by Onyinyechi Obidiro, Gantumur Battogtokh and Emmanuel O. Akala
Pharmaceutics 2023, 15(7), 1796; https://doi.org/10.3390/pharmaceutics15071796
“Biomarkers in Breast Cancer: An Old Story with a New End”
by Lyvia Neves Rebello Alves, Débora Dummer Meira, Luiza Poppe Merigueti, Matheus Correia Casotti, Diego do Prado Ventorim, Jucimara Ferreira Figueiredo Almeida, Valdemir Pereira de Sousa, Marllon Cindra Sant’Ana, Rahna Gonçalves Coutinho da Cruz, Luana Santos Louro et al.
Genes 2023, 14(7), 1364; https://doi.org/10.3390/genes14071364
“Could Microbiome Be the Common Co-Denominator between Type 2 Diabetes and Pancreatic Cancer?”
by Marin Golčić and Andrej Belančić
Diabetology 2023, 4(4), 553–559; https://doi.org/10.3390/diabetology4040049
“Targeting Solute Carrier Transporters (SLCs) as a Therapeutic Target in Different Cancers”
by Ravi Bharadwaj, Swati Jaiswal, Erandi E. Velarde de la Cruz and Ritesh P. Thakare
Diseases 2024, 12(3), 63; https://doi.org/10.3390/diseases12030063
“Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer”
by Dimitrios Stefanoudakis, Maximos Frountzas, Dimitrios Schizas, Nikolaos V. Michalopoulos, Alexandra Drakaki and Konstantinos G. Toutouzas
Curr. Issues Mol. Biol. 2024, 46(4), 2827–2844; https://doi.org/10.3390/cimb46040177
“Metformin: From Diabetes to Cancer—Unveiling Molecular Mechanisms and Therapeutic Strategies”
by Emilia Amengual-Cladera, Pere Miquel Morla-Barcelo, Andrea Morán-Costoya, Jorge Sastre-Serra, Daniel Gabriel Pons, Adamo Valle, Pilar Roca and Mercedes Nadal-Serrano
Biology 2024, 13(5), 302; https://doi.org/10.3390/biology13050302
“Immune Checkpoint Inhibitors: Fundamental Mechanisms, Current Status and Future Directions”
by Abdullah Younis and John Gribben
Immuno 2024, 4(3), 186–210; https://doi.org/10.3390/immuno4030013
“Breast Cancer Screening among African Immigrants in the United States: An Integrative Review of Barriers, Facilitators, and Interventions”
by Julian I. Rauch, Joseph Daniels, Alyssa Robillard and Rodney P. Joseph
Int. J. Environ. Res. Public Health 2024, 21(8), 1004; https://doi.org/10.3390/ijerph21081004
“Predicting Leukoplakia and Oral Squamous Cell Carcinoma Using Interpretable Machine Learning: A Retrospective Analysis”
by Salem Shamsul Alam, Saif Ahmed, Taseef Hasan Farook and James Dudley
Oral 2024, 4(3), 386–404; https://doi.org/10.3390/oral4030032
 |
 |
 |
 |
 |
28 January 2025
MDPI Open Science Insights: Academic Publishing Workshop at the University of Leeds, 12 March 2025
In collaboration with the University of Leeds (UK), Cancers (ISSN: 2072-6694) is hosting an academic publishing workshop designed to educate attendees on MDPI’s paper publication process and the ecosystem surrounding open access publishing. This session will cover a comprehensive introduction to the editorial process, ethics, and open access in the context of academic research, providing valuable insights and instilling essential skills for structuring papers and replying to reviewers effectively. Additionally, participants will be instructed on methods to improve their scientific writing and find the right journal to submit to, with experts in the field leading the session to ensure a thorough understanding of how attendees can escalate their publishing potential.
Schedule:
|
Time |
Programme and Content |
Speakers |
|
10 a.m.–12 p.m. |
|
Ms. Mary O’Sullivan |
|
12 p.m.–1 p.m. |
Lunch Break |
|
|
1 p.m.–3 p.m. |
|
Dr. Anya Osborn |
Speaker:
Name: Dr. Nic Orsi
Affiliation: Division of Pathology and Data Analytics
Leeds Institute of Medical Research, Wellcome Trust Brenner Building
Leeds, UK
Email: N.M.Orsi@leeds.ac.uk
Interests: oocytes; embryos; embryo culture; ovary; chemokines; TNF; implantation; vascular medicine; gametogenesis; systems biology
Dr. Nic Orsi obtained his BSc in Animal Science from the University of Reading in 1998 and his Ph.D. in Biology in 2002 from the University of York, UK. He then moved to the University of Leeds where he initially worked as a postdoc and then as a PI in Paediatrics, Obstetrics & Gynaecology before moving to Pathology in 2006. Whilst working at the University of Leeds, he also undertook his MBChB, which he completed in 2012. Thereafter, he completed his academic clinical foundation training before joining the Histopathology training program in 2014 at Leeds Teaching Hospitals Trust, both also working as a PI in the Wellcome Trust Brenner Building and as a Visiting Fellow at Harvard Medical School. Dr. Orsi now heads up the Women’s Health Research Group within Pathology in LIMR where his research interests focus principally on women’s cancers, reproductive pathology and biotechnology industrial partnerships. He is also Director of PGRS for LIMR and Vice-Chair of Leeds (East) Research Ethics Committee.
MDPI Speakers:
Ms. Mary O’Sullivan obtained her B.Sc. in genetics in 2019 and her M.Sc. in molecular cell biology with bio-innovation in 2020 from University College Cork in Ireland. She started her career at MDPI in January 2023 working for the Editorial Department of the journal Cancers as an Assistant Editor and, following this, a Section Managing Editor. Currently, Ms. O’Sullivan is a Journal Relations Specialist based in the UK office in Manchester.
Dr. Anya Osborn obtained her Ph.D. in auditory neuroscience from Keele University, UK, on a project developing cell replacement therapy to treat age-related hearing loss before joining MDPI in June 2020 as an Assistant Editor for Cancers. She then became a Journal Relations Specialist before becoming a Journal Relations Project Manager at the Manchester, UK office.
